Among patients with GCA, those with low vs high CRP levels more often presented with anterior ischemic optic neuropathy and limb claudication.

Results of a systematic review and meta-analysis showed that many multivariable models for predicting GCA have methodological flaws.

Health Canada has granted a Notice of Compliance (NOC) to AbbVie’s Rinvoq (upadacitinib) to treat adult patients diagnosed with chronic autoimmune vasculitis, giant cell arteritis (GCA).

(RTTNews) - AbbVie Inc. (ABBV), Wednesday announced Health Canada has issued a Notice of Compliance for RINVOQ for the treatment of adults with giant cell arteritis, both used in combination with a ...

Tune into our latest webinar which explores the diagnosis and day-to-day management strategies of giant cell arteritis (GCA). Expert in the field Qasim Akram, Stockport NHS Foundation Trust, UK, ...

Novartis has come up short in its bid to expand its blockbuster drug Cosentyx to an autoimmune disease whose only biologic treatment options are an old Roche drug and the biosimilars that have ...

Novartis (NYSE:NVS) (OTCPK:NVSEF) announced Thursday that its FDA-approved anti-inflammatory agent Cosentyx failed to reach the main goal in a Phase 3 trial for adults with giant cell arteritis ((GCA) ...

Cosentyx missed primary endpoint in GCA trial but reduced steroid use and toxicity compared to placebo. Cosentyx sales rose 16% year over year to $1.5 billion in Q1 2025, driven by demand across ...

The GCAptAIN study, which included patients with newly diagnosed or relapsing GCA, missed its primary endpoint of sustained remission at week 52. Topline results were announced from a phase 3 study ...

A common medication already used for autoimmune diseases such as rheumatoid arthritis is effective for patients with giant cell arteritis, according to findings from a team at the Perelman School of ...